CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 21 enrolled
Drug / intervention
colesevelam HCl +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00993824
NCT00993824Phase 3Completed
CompareCT.gov

Use of Continuous Glucose Monitoring With Ambulatory Glucose Profile Analysis to Demonstrate the Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

HealthPartners Institute·interventional·Posted Oct 14, 2009·Updated Nov 30, 2015

In Brief

A Phase 3 clinical trial evaluating colesevelam HCl and placebo for Type 2 Diabetes. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of this study is to obtain continuous glucose monitoring (CGM) data from individuals taking Welchol compared to placebo. The CGM data will determine the effect on glucose control of adding Welchol to an anti-diabetic medication regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsInternational Diabetes Center at Park Nicollet, Daiichi Sankyo

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 14, 2009
Enrollment StartSep 1, 2009
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.7 years ago

Interventions

colesevelam HCldrug

3.75 grams of colesevelam HCl (6 tablets)

placebodrug